Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 3/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | CES1 | P23141 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004335 | 0.86 | HDAC1 (0.57) | HDAC1HDAC6PARP1PTPN11CES2 | |
| SCHEMBL1233792 | 0.82 | TPMT (0.54) | HDAC1HDAC6CES2CES1TSHR | |
| SCHEMBL30601711 | 0.82 | TPMT (0.54) | HDAC1HDAC6CES2CES1TSHR | |
| SCHEMBL4495302 | 0.81 | HDAC1 (0.44) | HDAC1HDAC6CES2CES1TPMT | |
| SCHEMBL26340812 | 0.80 | HDAC1 (0.47) | HDAC1HDAC6PARP1PTPN11CES2 | |
| SCHEMBL16042892 | 0.78 | CA1 (0.47) | HDAC1HDAC6BPTFPARP1PTPN11 | |
| SCHEMBL22210664 | 0.78 | HDAC1 (0.42) | HDAC1HDAC6CES2CES1SMN1; SMN2 | |
| SCHEMBL524678 | 0.78 | KDM4E (0.48) | HDAC1HDAC6PTPN11TSHRCYP3A4 | |
| SCHEMBL3783315 | 0.77 | PARP1 (0.43) | HDAC1HDAC6BPTFPARP1PTPN11 | |
| SCHEMBL30727808 | 0.75 | NPSR1 (0.44) | HDAC1HDAC6CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313556-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RETUNE PHARMA, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4514799-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MRJA Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119384421-A | Certain chemical entities, compositions and methods | 沐尔佳治疗公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2023212612-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN SHAWN (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212612-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN SHAWN (US) | 2023-11-02 | — | — | WO | disclosed |
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| EP-2280943-B1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDO]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2013-11-06 | — | — | EP | disclosed |
| EP-2498775-A1 | NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES | Almirall S.A. (ES) | 2012-09-19 | — | — | EP | disclosed |
| CN-102026972-A | New substituted spiro[cycloalkyl-1,3'-indol]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | ALMIRALL SA | 2011-04-20 | — | — | CN | disclosed |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| WO-2011021678-A1 | FUSED HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2011-02-24 | — | — | WO | disclosed |
| EP-2280943-A1 | NEW SUBSTITUTED SPIROÝCYCLOALKYL-1,3'-INDOL¨-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | Almirall, S.A. (ES) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009124692-A1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | ALMIRALL, S.A. (ES) | 2009-10-15 | — | — | WO | disclosed |
| EP-2108641-A1 | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-10-14 | — | — | EP | disclosed |
| EP-1917241-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007000339-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313556-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIT, PRKCH, PRKCB | HDAC1 1005/4885HDAC6 1095/4885BPTF 1962/4885 |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | HDAC1 704/4885HDAC6 582/4885BPTF 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.